



INTERNATIONAL GASTROINTESTINAL
13TH
CANCERS CONFERENCE

Selectum Hotel Belek / Antalya

30 November-3 December 2023

SCIENTIFIC PROGRAM





30 November 2023, Thursday**PRE CONGRESS COURSES
(ONSITE)****MOLECULAR ONCOLOGY COURSE:
HOW TO ORDER AND EVALUATE MOLECULAR TESTS**

Course Chairs: Mustafa Özdoğan, Axel Grothey, Şuayib Yalçın

16:00-16:20	Introduction to basic concepts Taha Bahsi (DNA analysis, RNA analysis, amplifications, mutations, VUS, copy number variations, methylation, fusions, transcriptomics, metabolics, protein expressions, proteomics, immune histochemistry, NGS, Sanger)
16:20-17:00	Clinical applications Georgios Nasioulas (RET, ALK, NTRK, FGFR, HER-2, ROS, POLE/D, IDH, EGFR, RAS, PI3CA, Claudins, BRAF, CKIT, PGDFR, BRCA, MGMT, PTEN, MDM2, MSI/MMRD, PDL-1/CPS/TPS, DDR)
17:00-17:20	Broad or focused molecular profiling Axel Grothey
17:20-17:40	Complex gene signature analysis/pathway analysis Osman Uğur Sezerman
17:40-18:00	Liquid biopsies when and how it can help Şahin Laçın
18:00-18:20	Emerging role of ctDNA in GI oncology Deniz Can Güven
18:20-18:40	Bioinformatics for precision medicine in oncology Georgios Tsaousis
18:40-19:00	Case discussions

30 November 2023, Thursday

PRE CONGRESS COURSES
(ONSITE)

MICROBIOTA AND GASTROINTESTINAL CANCER

Course Chairs: John Souglakos, Ömer Dizdar, Ilias Athanasiadis

13:30-14:00	Microbiota in health and disease: Basic concepts, functions, diversity, dysbiosis Nurdan Tözün
14:00-14:40	Methods in microbiome research 14:00-14:20 Workflow for microbiome studies: From sampling to microbial population analysis Ceren Özkul  ZOOM 14:20-14:40 Shotgun metagenomics and bioinformatics Osman Uğur Sezerman
14:40-15:00	Microbiome and cancer: Focus on GI cancers Tarkan Karakan  ZOOM
15:00-15:20	Coffee break and networking
15:20-15:40	Microbiome as a biomarker for cancer: Single species, oncomicrobiome signatures Ayberk Beşen • Screening • Diagnosis • Prognosis
15:40-16:10	Microbiome as a predictor for response to treatment 15:40-16:30 Chemotherapy, targeted therapy Tarkan Yetişyiğit 15:40-15:55 Immunotherapy Ömer Dizdar 15:55-16:10 Radiotherapy Pervin Hürmüz  ZOOM
16:10-16:40	Targeting microbiota in cancer treatment: Current and emerging strategies 16:10-16:25 Pre/probiotics and engineered bacterial products Nazlı Dizman  ZOOM 16:25-16:40 Diet and antibiotics Metin Demir
16:40	Closing & remarks Şuayib Yalçın, John Souglakos

30 November 2023, Thursday

PRE CONGRESS COURSES
(ONSITE)

NUTRITION ONCO CAMP

14:00-14:20	Opening speech: Current situation in nutrition in oncology: Pronto Şuayib Yalçın
14:20-14:50	Nutritional needs in oncology Chair: Şuayib Yalçın Speakers: Berna Öksüzoğlu
14:50-15:30	Muscle loss and the importance of muscle in oncology patients & HMB clinical studies Chairs: Nil Molinas Mandel, Gökhan Demir Speaker: Maria Camprubi Experience with HMB (case presentation): Elvina Almuradova
15:30-16:00	Coffee Break
16:00-16:20	Positive effect of nutrition on cancer treatment Chairs: Gökhan Demir, Nil Molinas Mandel Speakers: Şeyda Gündüz, Berksoy Şahin
16:20-16:50	How to select?: Nutritional products in oncology patients Chair: Erdem Göker, Mahmut Gümüş Speakers: Bülent Orhan, Evrim Güngör
16:50-17:00	Coffee Break
17:00-17:30	Planning nutritional support and increasing compliance in oncology treatment Chair: Erdem Göker, Türkkan Evrensel Speaker: Ece Esin
17:30-18:00	Importance of nutrition in oncology with cases: 2 cases Chair: Şeref Kömürcü Speakers: Bülent Orhan, Dilşat Baş
18:00	Closing

30 November 2023, Thursday

ONLINE CONFERENCE PROGRAM






08:30-10:45	<p>Update on the current standards of immunotherapy for gastrointestinal cancers Chairs: Handan Onur Topuzlu, Jesus Garcia Foncillas, Fuat Demirelli</p> <p>08:30-09:00 Basics and rationale for IO treatment in GI cancer Derya Kivrak Salim</p> <p>09:00-09:15 Esophageal cancer Blijana Grozdanoska</p> <p>09:15-09:30 Gastroesophageal and gastric cancer Gürkan Güner</p> <p>09:30-09:45 Hepatocellular cancer Hakan Taban</p> <p>09:45-10:00 Biliary cancers Yasemin Kemal</p> <p>10:00-10:15 Pancreatic cancer Barış Aykan</p> <p>10:15-10:30 Colorectal cancer Metin Demir</p> <p>10:30-10:45 Anal cancer Okan Avci</p>
11:00-12:00	<p>Tumor board: Esophagogastric and gastric cancer Chairs: Markus Moehler, Vlademir Nikolic, Türkan Evrensel</p> <p>11:00-11:15 Case #1: Her-2 overexpressed Osman Sütçüoğlu</p> <p>11:15-11:30 Case #2: MSI high Ali Alkan</p> <p>11:30-11:45 Case #3: Metastatic disease going thru treatment lines Emir Sokolovic</p> <p>11:45-12:00 Case 4: Metastatic disease with low CPS/PdI expression Ertuğrul Bayram</p>

<p>12:15-13:30</p>	<p>From minimal invasive approach to cytoreductive surgery in colorectal cancer Chairs: Halis Şimşek, Osman Abbasoğlu, Berksoy Şahin</p> <p>12:15-12:30 Hepatic artery infusion chemotherapy for colorectal liver metastases: what is old is new again Sepideh Gholami</p> <p>12:30-12:45 Surgical management of peritoneal disease in CRC Ali Ekrem Ünal</p> <p>12:45-13:00 Evaluation of the current cytotoxic regimens used with hyperthermia after CRS Şeyda Gündüz</p> <p>13:00-13:15 Role of endoscopist in the treatment of early CRC Cem Şimşek</p> <p>13:15-13:30 Case discussion: minimally invasive colon cancer treated with EMR Case: Hasan Çağrı Yıldırım</p> <p>Discussants: Ethem Geçim, Timuçin Erol</p>
<p>13:30-15:50</p>	<p>Management of biliary cancers Chairs: Handan Onur Topuzlu, Dinç Süren, Ola Khorsid</p> <p>13:30-13:45 Pathological aspects of biliary cancers Armağan Günel</p> <p>13:45-14:00 Radiologist assesment of biliary cancers Vesna Sarajlic</p> <p>14:00-14:15 Surgery Alihan Gürkan</p> <p>14:15-14:30 Role of radiotherapy Yasemin Bölükbaşı</p> <p>14:30-14:45 Adjuvant treatment İrem Bilge Tekin</p> <p>14:45-15:00 Role of hepatic arterial therapy including HAIC, TARE and TACE Bora Peynircioğlu</p> <p>15:00-15:15 Systemic treatment: Chemotherapy options for the first line and beyond Mutlu Doğan</p> <p>15:15-15:30 Systemic treatment: Targeted therapies Özlem Yersal</p> <p>15:30-15:45 How far can we go with immune check point inhibitors Fatih Köse</p> <p>15:45-15:50 Case Speaker: Cholangiocarcinoma Latif Karahan</p>

15:50-16:15	<p>Expanding role antibody drug conjugates in GI oncology: Where do we stand today?</p> <p>Chairs: Hüseyin Mertsoylu, Ali Shamseddin</p> <p>Sema Türker</p>
16:30-17:00	<p>Update on the mangement of neutropenia and emesis in GI cancer patients</p> <p>Chairs: Ahmet Demirkazık, Özgür Özyılkan</p> <p>16:30-16:45 Management of chemotherapy induced neutropenia Serkan Akın</p> <p>16:45-17:00 Management of chemotherapy induced emesis Neyran Kertmen</p>
17:00-18:45	<p>Pancreatic cancer: Emerging concepts and treatments for metastatic disease</p> <p>Chair: Hakan Akbulut</p> <p>17:00-17:15 Management of IPMN Anıl Dinçer</p> <p>17:15-17:30 Hereditary and familial pancreatic cancer Yasin Burak Aktaş</p> <p>17:30-17:45 Ras wild type pancreatic cancer: a different entity Oktay Aktepe</p> <p>17:45-18:00 Characteristic of RAS mutant pancreatic cancer Arzu Yaşar</p> <p>18:00-18:15 RAS as a treatment target in pancreatic cancer Eda Çalışkan Yıldırım</p> <p>18:15-18:30 Role of immune check point inhibitors İlkay Tuğba Ünek</p> <p>18:30-18:45 Vaccines and CART cells Yeşim Yıldırım</p>

18:45-19:45	<p>Basics of approved targeted therapies for the metastatic colon cancers Chairs: Al Benson, Ece Esin</p> <p>18:45-19:00 Anti VEGF therapies Mehmet Akif Öztürk</p> <p>19:00-19:15 The biologic explanations of time related effects of bevacizumab: why bevacizumab has a good PFS benefit but not an overall survival alone. Dan Aderka</p> <p>19:15-19:30 Anti EGFR therapies Jesus Garcia Foncillas</p> <p>19:30-19:45 Immune check point inhibitors Markus Moehler</p>
19:45-20:00	<p>Oral abstract session – 1 Chairs: Oktay Aktepe, Hacer Demir</p> <p>19:45-19:50 OP-20 Sex and gender differences in colon cancer Anes Pasic</p> <p>19:50-19:55 OP-21 A multimodal approach to proximal esophageal squamous cell carcinoma Emir Sokolovic</p> <p>19:55-20:00 OP-22 Radiologist assessment of biliary tract cancers Vesna Sarajlic</p> <p>20:00-20:05 OP-23 Is concurrent standard mediastinal lymph node dissection required in patients who have undergone pulmonary metastasectomy for colorectal cancer? Ulas Kumbasar</p> <p>20:05-20:10 OP-24 Evaluation of neoadjuvant treatment results in elderly with locally advanced stage rectal cancer (LARC) Oğuzhan Başçık</p> <p>20:10-20:15 OP-26 Vertebral compression fracture after radiotherapy in patients with gastric cancer Yasin Ozyurek</p> <p>20:15-20:20 OP-28 Adjuvant radiotherapy outcomes in pancreatic cancer – A single-center experience Fatma İlay Korkmaz</p>

1 December 2023, Friday

	HALL A	HALL B	HALL C
08:00-09:00	<p>Meet the Prof</p> <p>Hepatocellular cancer</p> <p>Chair: Murat Koçer</p> <p>Speaker: Ahmed Kaseb</p> <p>Participants: İlkay Tuğba Ünek, Rakhim Abdurassulov</p>	<p>Meet the Prof</p> <p>Advanced colon cancer</p> <p>Chairs: Şeref Kömürçü, Ofer Purim</p> <p>Speaker: Dirk Arnold </p> <p>Participants: Halil İbrahim Ellez, Fatma Aydoğan</p>	<p>Meet the Prof</p> <p>Gastric cancer</p> <p>Chairs: Erkan Doğan, Tebessüm Çakır, Ivane Kiladze</p> <p>Speaker: David Ilson </p> <p>Participants: Orhan Aras, Narmin Talibova, Seval Akay</p>
09:00-09:45	<p>Artificial intellegice in oncology</p> <p>Chairs: Şuayib Yalçın, Philip Agop Philip, Dan Aderka , Ilias Athanasiadis, Axel Grothey, David Ilson </p> <p>Speaker: Ido Wolf </p>		

13th INTERNATIONAL GASTROINTESTINAL CANCER CONFERENCE


	HALL A	HALL B	HALL C
09:45-11:00	<p>Pancreatic cancer Chairs: Ali Arıcan Nuri Karadurmus </p> <p>09:45-10:00 Surgical aspects of pancreatic cancer Ahmet Bülent Doğrul</p> <p>10:00-10:15 Genetic and tumor genomic factors Marwan Ghosn </p> <p>10:15-10:30 Adjuvant and perioperative treatment of resectable pancreas cancer Ebru Çilbir</p> <p>10:30-10:45 Role of radiotherapy in the management of pancreatic cancer Vildan Kaya</p> <p>10:45-11:00 Current systemic treatment for advanced disease Eric Van Cutsem</p>	<p>Sociodemocratic factors in the colon cancer Chair: Aziz Karaoğlu</p> <p>09:45-10:00 Early onset colon cancer Ilias Athanasiadis</p> <p>10:00-10:15 Colorectal cancer in the elderly Baran Akagündüz</p> <p>10:15-10:30 Gender differences Anes Pasic </p> <p>10:30-10:45 Colorectal cancer in low-middle income countries Ivane Kiladze</p> <p>10:45-11:00 Colon cancer in Turkey Ayşegül Kargı</p>	
11:00-11:30	Coffee Break and Networking		
11:30-12:15	<p>New practice in the treatment of 1st Line metastatic upper GI Cancers: Nivolumab+Chemotherapy Chair: Ömer Dizdar Speaker: Dilek Erdem</p>		
12:15-12:35	<p>Building strategies for a longer survival in metastatic colorectal cancer Chairs: İdris Yücel, Ido Wolf </p> <p>The superior value of neoadjuvant vs. adjuvant immunotherapy in cancer: the role of surgery induced immune suppression Dan Aderka </p>		

13th INTERNATIONAL GASTROINTESTINAL CANCER CONFERENCE



	HALL A	HALL B	HALL C
12:35-14:00	Lunch		
14:00-15:15	<p>Tissue agnostics pathways as treatment targets in GI cancers Chairs: Işıl Somali, Anwaar Saeed</p> <p>14:00-14:15 Role of HRD/DDR in treatment decision Öztürk Ateş</p> <p>14:15-14:30 Targeting claudin 18-2 in Gastric Cancer Ofer Purim</p> <p>14:30-14:45 RET alterations as treatment targets in GI cancers Bülent Orhan</p> <p>14:45-15:00 NTRK rearrangements in metastatic colorectal cancer İsmail Ertürk</p> <p>15:00-15:15 NRG1 and NRG2 alterations in GI cancers Hacer Demir </p> <p>Panelists: Burcu Ulaş Kahya, Feride Yılmaz, Seda Kahraman</p>	<p>Hepatocellular cancer: It is better to prevent than treatment</p> <p>Chairs: Ramazan İdilman, Halil Kavğacı, Ahmed Kaseb</p> <p>14:00-14:15 Does aspirin or statins have a role in chemoprevention of HCC Yasemin Balaban</p> <p>14:15-14:30 Viral hepatitis Osman Çağın Buldukoğlu</p> <p>14:30-14:45 Alcohol and HCC Serdar Karakaya</p> <p>14:45-15:00 NASH Amer Nabil Ishaq Sughayyer </p> <p>15:00-15:15 Diabetes Günel Musayeva</p> <p>15:15-15:30 Screening and surveillance Türkan Öztürk Topçu</p>	
15:30-16:15	<p>GIS and beyond with stivarga Speakers: Şahin Laçın, Ece Esin</p>		
16:15-17:00	<p>Impact of molecular profiling on treatment decisions in gastrointestinal malignancies Chair: Mustafa Özdoğan Speaker: Georgios Nasioulas</p>		 Genekor <small>Committed to Biotechnological Innovation</small>
17:00-17:30	Coffee Break and Networking		

13th INTERNATIONAL GASTROINTESTINAL CANCER CONFERENCE

	HALL A	HALL B	HALL C
17:30-18:15	<p>Round table</p> <p>Esophageal cancer management</p> <p>Chairs: Tuğba Yavuzşen, Mine Genç, John Souglakos</p> <p>Reporter: Ertuğrul Bayram</p> <p>17:30-17:45 Surgical perspective Tebessüm Çakır</p> <p>17:45-18:00 How should I treat in 2023 general overview Jamal Khader</p> <p>18:00-18:15 Systemic treatment options for advanced esophageal cancer Mehmet Artaç</p> <p>Panelist: Saadet Sim Yıldırım, Simay Çokgezer</p>	<p>Round table</p> <p>Anal cancer</p> <p>Chairs: Nilüfer Bulut, Marc Peeters</p> <p>Reporter: Gunel Musayeva</p> <p>17:30-17:45 Pathological evaluation of anal cancer Arsenal Sezgin Alikanoğlu</p> <p>17:45-18:00 Advances in tse multimodality treatment for localized disease Özlem Er </p> <p>18:00-18:15 New systemic treatment options for metastatic disease Ola Khorsid </p> <p>Panelists: Serkan Yaşar, Naziye Ak</p>	<p>Round table Ras Mutations in colon cancer: Light on the horizon</p> <p>Chairs: İlhan Öztop, Ioannis Boukovinas, Saadettin Kılıçkap</p> <p>17:30-17:35 OP-10 Evaluation of KRAS and NRAS mutations in an 8-year study of over 10000 samples for guiding the treatment of patients with metastatic colorectal cancer in Turkey Gözde Kavgacı</p> <p>17:35-17:50 Characteristics of RAS mutant tumors Faysal Dane</p> <p>17:50-18:05 Targeting Ras mutations: where do stand today Hande Turna</p> <p>18:05-18:30 New drugs, approaches on the horizon Sana Alsukhun </p> <p>18:30-18:45 Case discussion Gözde Kavgacı</p> <p>Discussants: Elif Atağ Akyürek, Burak Utku Bozbulut</p>

	HALL A
18:15-19:15	<p>Advances in the treatment of gastric and esophageal adenocarcinomas</p> <p>Chairs: Bülent Karabulut, Shouki Bazarbashi, Samira Mahmudova</p> <p>18:15-18:30 What has changed from surgical operspective Hüseyin Çiyiltepe</p> <p>18:30-18:45 Perioperative chemotherapy or neoadjuvant chemoradiotherapy for GEJ and gastric adenocancers: choosing right strategy to the right patient Yeşim Eralp </p> <p>18:45-19:00 Immune check point inhibitors in neoadjuvant and adjuvant setting Dilşa Mızrak Kaya</p> <p>19:00-19:15 Emerging systemic treatment options GEJ and gastric adenocarcinoma Anwaar Saeed</p>

2 December 2023, Saturday

	HALL A	HALL B	HALL C
08:00-09:30	<p>Diagnostic and theranostic nuclear medicine in GI cancers</p> <p>Chairs: Özlem Küçük, Murat Fani Bozkurt</p> <p>08:00-08:15 Current practice of FDG PET/CT imaging in GI tumors Gonca Bural</p> <p>08:15-08:30 PET/MRI as a novel molecular imaging modality for GI tumors Mine Araz</p> <p>08:30-08:45 FAPI: A New player in molecular imaging of GI Tumors Murat Tuncel</p> <p>08:45-09:00 TARE for GI tumors in the era of theranostics Bilge Volkan Salancı</p> <p>09:0-09:15 Alpha Theranostics for GI tumors Nalan Alan</p> <p>Discussion: Mehmet Cihan İçli, Hüseyin Engin</p>	<p>Pancreatic Cancer: Case discussions</p> <p>Moderators: Birol Bostancı, Aylin Fidan Korçum,</p> <p>Case Speaker: Çağatay Aslan</p> <p>Adjuvant Borderline Locally advanced Case Speaker: Tuğba Akın Telli</p> <p>Metastatic (Kras mutant, Kras wild, BRCA mutant, Good responder)</p> <p>Discussion: Ivane Kiladze, Fatih Kuş</p>	<p>Metastatic colorectal cancer management with daily practice cases</p> <p>Moderators: Gökhan Demir  ZOOM Mustafa Yıldız, Claus Henning Koehne</p> <p>Sequencing treatments beyond second line Ali Shamseddin  ZOOM</p> <p>Case Speakers: Fatih Köse, Cengiz Karaçin, Arif Akyıldız</p> <p>Case #1: Colon - 1 Case #2: Colon - 2 Case #3: Colon - 3 Discussion: Ilgın Koç, Merve Özkan</p>

13th INTERNATIONAL GASTROINTESTINAL CANCER CONFERENCE

	HALL A	
09:30-10:15	<p>Localized rectal cancer Chairs: Şeref Kömürçü, Halil İbrahim Şahin, Marwan Ghosn </p> <p>09:30-09:45 Do we need surgery in all patients Ethem Geçim</p> <p>09:45-10:00 Do we need radiation in all patients Uğur Seleğ</p> <p>10:00-10:15 From the medical oncologist perspective Sara De Dosso</p>	
10:15-10:45	Coffee Break and Networking	
10:45-11:45	<p>Management of GEP-NETs Chairs: Hakan Akbulut, Banu Öztürk, Tamer Elkıran </p> <p>10:45-11:05 Update on the classification of GEPNET Özcan Yıldız</p> <p>11:05-11:25 Overview of diagnosis and management of GEPNET Christos Toumpanakis </p> <p>11:25-11:45 Optimal sequencing of treatment options in GEPNET Philip Agop Philip</p>	
11:45-12:30	<p>ERBİTUX with mCRC from past to present: 19 Years of world experience</p> <p>Moderator: Şuayib Yalçın Speaker: Timuçin Çil</p>	
12:30-13:45	Lunch	
13:45-14:30	<p>Optimising 1st line treatment strategies for RAS wild-type metastatic CRC Chair: Şuayib Yalçın Speaker: Marc Peeters</p>	
14:30-15:30	<p>A closer look on the lines of treatment in colon cancer-1 Chairs: Erdem Göker, Aytağ Üner, Sana Alsukhun </p> <p>14:30-14:45 Is Neoadjuvant treatment becoming a standart approach in localized colon cancer Halil İbrahim Şahin</p> <p>14:45-15:00 Personalizing adjuvant treatment John Souglakos</p> <p>15:00-15:15 Who should get triplet regimen as first line treatment Dirk Arnold </p> <p>15:15-15:30 IO Immunotherapy in MSS coleraktal cancers: How to make MSI negative colon cancer sensitive to Dan Aderka </p>	

HALL A	
15:30-16:00	<p>Challenges of GI clinical trials: Experience of PIs from practice-changing studies Chair: Şuayib Yalçın Speakers: Axel Grothey, Philip Agop Philip, Dirk Arnold , David Ilson </p>
16:00-16:30	Coffee Break and Networking
16:30-17:15	<p>Meet The Expert Targeting RAS wild-type metastatic CRC: Management with daily practice cases </p> <p>Case speakers Moderator: Şuayib Yalçın Case #1: Deniz Can Güven Case #2: Tuğba Akın Telli Discussant: Marc Peeters</p>
17:15-17:35	<p>Keynote Lecture</p> <p>A Closer Look on the lines of treatment in colon cancer - 2 Chairs: Eric Van Cutsem, Zafer Arık</p> <p>17:15-17:35 Role of maintenance therapy Ece Esin</p>
17:35-18:05	<p>Chair: Ece Esin</p> <p>BostonGene at a glance Speaker: Barış Akmansoy  </p> <p>BostonGene tumor portrait test Speaker: BostonGene Corp. Head Quarter </p>
18:05-18:45	<p>Round table: Focusing on antiEGFR treatment in advanced CRC</p> <p>Moderators: Ahmet Özet, Hakan Harputluoğlu 18:05-18:15 Mechanisms of action and resistance to AntiEGFR moAb Claus Henning Koehne</p> <p>18:15-18:30 Is there a role for AntiEGFR rechallenge or use post progression Hüseyin Abalı</p> <p>18:30-18:45 Role of antiEGFR moAb as a part of neoadjuvant and induction treatment Marc Peeters</p> <p>Panelist: Arif Akyıldız</p>
18:45-19:00	<p>Creating international networks to conduct high-quality research: ESMO-ESO-EORTC experience</p> <p>Moderators: Deniz Can Guven, Necdet Üskent Panelists: Eric Van Cutsem, John Souglakos, Sara De Dosso</p>

3 December 2023, Sunday

	HALL A	HALL B
08:45-09:15	<p>Lets talk about claudins for GI cancers Chairs: Ulus Ali Şanlı, Abdurassulov Rakhim</p> <p>08:45-09:00 Role of claudins in GI cancers Ramazan Oğuz Yüceer</p> <p>09:00-09:15 Targeting claudin pancreatic cancer Elvina Almuradova</p>	<p>Oral abstract session - 2 Chairs: Nilay Şengül, Nail Paksoy, Burak Utku Bozbulut</p> <p>Discussants: Gözde Kavgacı, Barış Köksal</p> <p>08:45-08:50 OP - 01 08:50-08:55 OP - 02 08:55-09:00 OP - 03 09:00-09:05 OP - 04 09:05-09:10 OP - 05 09:10-09:15 OP - 06 09:15-09:20 OP - 07 09:20-09:25 OP - 08 09:25-09:30 OP - 09 09:30-09:35 OP - 11 09:45-09:40 OP - 12 09:40-09:45 OP - 13 09:45-09:50 OP - 14 09:50-09:55 OP - 15 09:55-10:00 OP - 16 10:00-10:05 OP - 17 10:05-10:10 OP - 18 10:10-10:15 OP - 19 10:15-10:20 OP - 25 10:20-10:25 OP - 27</p>
	HALL A	
09:15-10:15	<p>Precision oncology-1 We can better understand and treat GI cancers using genomic and genetic data Chairs: Sara De Dosso, Güngör Utkan</p> <p>09:15-09:30 HER-2 directed therapies Canan Karan</p> <p>09:30-09:45 BRAF mutant mCRC Özkan Kanat</p> <p>09:45-10:00 MGMT İbrahim Petekkaya</p> <p>10:00-10:15 MSI Nazım Can Demircan</p>	

	HALL A
10:15-11:30	<p>Hepatocellular tumors Chairs: Faruk Aykan, Gökhan Çelenkoğlu</p> <p>10:15-10:30 Surgical management of HCC Sepideh Gholami</p> <p>10:30-10:45 Emerging role of systemic therapies at earlier stages Mehmet Ali Nahit Şendur</p> <p>10:45-11:00 Treatment of BCLC-B stage: New approaches Bora Peynircioğlu</p> <p>11:00-11.15 Radiation treatment for HCC: Which patient and how Pervin Hürmüz </p> <p>11:15-11:30 Optimal sequencing of the systemic treatments Ahmed Kaseb</p>
11:30-12:00	Coffee Break and Networking
12:00-12:30	<p>GIST Chairs: Cenk Sökmensüer, Alper Sevinç</p> <p>12:00-12:15 Pathological aspects of GIST Volkan Adsay</p> <p>12:15-12:30 Molecular biology of GIST Tülay Akman</p>
12:30-13:00	<p>Update on systemic treatment of GIST Chairs: Osman Köstek, Fatih Selçuk Biricik</p> <p>12:30-12:45 Adjuvant Shouki Bazarbashi</p> <p>12:45-13:00 Metastatic Ioannis Boukovinas</p> <p>Discussant: Latif Karahan</p>
13:00	Awards - Closing Remarks

08:45-09:15

ABSTRACT PROGRAMME

08:45-08:50 OP-01

Pathological responses post total neoadjuvant therapy (TNT) in locally advanced rectal cancer

Sania Walid Abdelqader

08:50-08:55 OP-02

Are mGPS, SIS and LCS significant in predicting first-line palliative chemotherapy response and prognosis in patients with metastatic gastric cancer?

Yaşar Culha

08:55-09:00 OP-03

Clinical and pathological evaluation of INSM1 immunohistochemical expression in gastric neuroendocrine tumors

Kamuran Yüceer

09:00-09:05 OP-04

The accuracy of the patient information data provided by ChatGPT about gastric cancer

Burcu Ulaş Kahya

09:05-09:10 OP-05

The Effect of adjuvant chemotherapy initiation time on survival in high-risk stage II and stage III colon cancer

Metin Demir

09:10-09:15 OP-06

The effect of intraoperative microwave ablation and resection on survival in liver metastases of noncolorectal cancers: A single-center retrospective clinical study

Sera Yazıcı

09:15-09:20 OP-07

Comparative efficacy analysis of adjuvant chemotherapy regimens with and without oxaliplatin in two centers with stage-3 colon cancer in patients over 70 years of age

Duygu Özaşkın

09:20-09:25 OP-08

Clinical outcomes of the safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study

Arif Akyıldız

09:25-09:30 OP-09

Impact of HER2-low status in metastatic gastric cancer

Seval Akay

09:30-09:35 OP-11

The effect of hepatic resection combined with microwave ablation on survival and local recurrence in bilobar liver metastases of colorectal cancer

Dogukan Dogu

09:45- 09:40 OP-12

Efficacy of irinotecan mono-chemotherapy and doublet-chemotherapy regimens for second-line settings for patients with metastatic gastric cancer progressing after first-line Platinum-based chemotherapy

Abdulmunir Azizy

09:40-09:45 OP-13

Neo-ras wild phenomenon

Merve Özkan

09:45-09:50 OP-14

Serum EGFR Level as prognostic indicator for patients with hepatocellular carcinoma: Insights from a Turkish Cohort Study

Rohat Esmer

09:50-09:55 OP-15

YEL scoring system: A superior tool for liver disease prognosis compared to child-turcotte-pugh class

Rohat Esmer

09:55-10:00 OP-16

Dosimetric factors associated with postoperative pulmonary complications and length of stay in the intensive care unit in patients with locally advanced esophageal cancer treated with pre-operative chemoradiotherapy

Barbaros Aydın

10:00-10:05 OP-17

Heterogenous Nature of the microsatellite status should be considered in the treatment of gastric cancer: beware of immunotherapy alone ?

Mirac Ajredini

10:05-10:10 OP-18

Yttrium-90 radioembolization treatment in unresectable cholangiocarcinoma: single centre retrospective dosimetry, response and survival analysis

Aylin Ormanci

10:10-10:15 OP-19

Effect of enhanced recovery after surgery protocol on clinical outcomes in elective colorectal surgery

Kamal Magsudlu

10:15-10:20 OP-25

The role of radiotherapy for unresectable cholangiocarcinoma

Alper Kahvecioglu

10:20-10:25 OP-27

A nomogram for predicting overall survival in gastric cancer patients receiving adjuvant chemoradiotherapy

Ecem Yiğit



SCIENTIFIC SECRETARIAT



Prof. Dr. Şuayib Yalçın

Hacettepe University Institute of Oncology Department of
Medical Oncology

E-mail: syalcin@hacettepe.edu.tr

ORGANIZATION SECRETARIAT



UNICON Congress and Organization Services Inc.

Kültür Mah. Kartal Sk. İşyerleri Blok

No: 5 Beşiktaş / İstanbul

Phone: +90 (538) 092 80 39 • +90 (532) 713 53 35

URL: www.unicon.com

E.mail: info@igicc.org, igicc@unicon.com